« Media center

Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid® Ge

Helsinn Healthcare SA

Lugano, Switzerland, December 1, 2016: Helsinn Integrative Care, Helsinn’s business unit focused on evidence-based, non-pharmaceutical cancer supportive care products, today announces that Xonrid® Gel, a topical gel for radiotherapy-induced dermatitis, already classified as a medical device in the EU, has received 510(K) FDA clearance in the US.

This now allows Xonrid® Gel to be marketed in the US for the management and relief of the burning and itching experienced by patients with radiation dermatitis.